The American peptide drug market is experiencing an unprecedented boom, and bitcoin plays a key role in this. In the first quarter of 2026, sellers of such products received $32 million in cryptocurrency from clients, a 700% increase compared to the same period last year. These are drugs positioned as weight loss, muscle building, and anti-aging remedies.

Legal peptides undergo clinical trials and are sold through major pharmacy chains like Walgreens and CVS. However, a significant portion of online trade goes into a gray zone: cheap analogs are imported from foreign laboratories without a prescription or insurance. Many packages even carry a label stating they are not intended for human use — a formal way to bypass regulation.

Why cryptocurrency?

Traditional banks and card networks refuse to service such sellers due to high compliance risks. As a result, some suppliers accept payment exclusively in bitcoin. Notably, for many buyers, this becomes their first experience with digital assets. A striking example is 49-year-old marketing director Zack from the northwestern states. Searching for the drug retatrutide, he found a Chinese supplier who agreed to ship 20 vials for just $240 — compared to $300 per month on the U.S. market. The seller only accepted cryptocurrency, and Zack had to buy bitcoin for the first time in his life.

Market dynamics: from underground to mainstream

Analysis of on-chain data reveals three stages in the evolution of this market. Before 2025, it was a niche "underground" with a monthly inflow of about $200,000. Then the topic came into the spotlight of the Make America Healthy Again movement, coinciding with the appointment of Robert F. Kennedy Jr. as head of the U.S. Department of Health and Human Services. Although no direct causal link is evident from blockchain data, the coincidence is significant.

The real explosion occurred in late 2025, when the topic entered the TikTok subculture of looksmaxxing — a community obsessed with improving appearance and physical fitness. The average monthly inflow quadrupled to $9.9 million, and in peak months exceeded $10 million.

For comparison, according to estimates by former Coinbase Global employee Sarah Graham, the annual turnover of the peptide market was about $100 million as early as 2023. According to TRM Labs data, in 2025, digital asset inflows into this sector reached $41.4 million — a 20% increase year-over-year. TRM Labs' global director of policy, Ari Redbord, draws a parallel with the early stages of shadow online markets like Silk Road.

Major players shift to stablecoins

The market is unevenly structured: the bulk of volume comes from a narrow group of large sellers. Small players experiment with various coins, but large suppliers use almost exclusively bitcoin and stablecoins. Sellers with an average deposit of $1,000 or more predominantly use "stablecoins" — this hedges against volatility in large and cross-border purchases.

The primary raw materials for peptides are produced in China. According to Forbes, over the three quarters of last year, imports from China to the U.S. doubled to over $300 million. Notably, some suppliers have transitioned into peptides from the drug trade. For example, the Chinese company Bigreat Technology, which previously supplied precursors for fentanyl and amphetamines to markets in Russia and Kazakhstan, set up a separate legal entity — Zhengzhou DEPU Technology — to sell cosmetic peptides.

My comment: This case is a classic example of how regulatory barriers and price pressure create new niches for cryptocurrencies. Here, bitcoin acts not as an investment asset, but as a tool for financial inclusion for markets rejected by the traditional banking system. However, investors should remember: the growth of such a segment always comes with heightened legal risks, and regulators will sooner or later turn their close attention to it.